Vanguard Capital Management
ERNA icon

Vanguard Capital Management’s Eterna Therapeutics ERNA Stock Holding History

Vanguard Capital Management’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.8K Buy
5,684
+4,624
+436% +$32.9K ﹤0.01% 3962
2026
Q1 		$5.27K Buy
+1,060
New +$16.9K ﹤0.01% 4034

Other funds holding ERNA

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
TCM
Tradewinds Capital Management Bellingham, Washington $563M AUM 41.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

Vanguard Capital Management's ERNA Position: Q2 2026 in Review

Vanguard Capital Management increased its Eterna Therapeutics (ERNA) stake by 436% in Q2 2026, buying an estimated $32.9K and bringing the position to 5,684 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3962.

Vanguard Capital Management first reported a position in ERNA in Q1 2026 and has held it in 2 quarters since. 9 funds tracked by Wall St. Rank hold ERNA as of Q2 2026.

  • Vanguard Capital Management held 5,684 shares of Eterna Therapeutics worth $37.8K as of Q2 2026.
  • Vanguard Capital Management bought 4,624 Eterna Therapeutics shares in Q2 2026, an estimated $32.9K.
  • Eterna Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3962 holding.
  • Vanguard Capital Management first reported a position in Eterna Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 9 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.